243
Views
35
CrossRef citations to date
0
Altmetric
Original Article

Inhibition of ovulation by a novel progestogen (drospirenone) alone or in combination with ethinylestradiol

, , , , , , , , & show all
Pages 16-24 | Accepted 24 Mar 2000, Published online: 06 Jul 2009

REFERENCES

  • Losert W, Casals-Stenzel J, Buse M. Progestogens with antimineralocorticoid activity. Arzneim Forsch/Drug Res 1985; 35: 459–71
  • Nickisch K, Beier S, Bittler D, et al. Aldosterone antagonists. 4. Synthesis and activities of steroidal 6,6–ethylene-15,16–methylene 17–spironolactones. J Med Chem 1991; 34: 2464–8
  • Muhn P, Krattenmacher R, Beier S, et al. Drospirenone, a novel progestogen with antimineralocorticoid and antiandrogenic activity. Contraception 1995; 51: 99–110
  • Oelkers W, Berger V, Bolik A, et al. Dihydro-spirorenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin–aldosterone system in normal women. J Clin Endocrinol Metab 1991; 73: 837–42
  • Krattenmacher R, Fromm M. Mineralocorticoid and antimineralocorticoid effects of various progestogens on electronic Na+ transport in the rat distal colon in vitro. In Abstracts of the 36th Symposium of the Deutsche Gesellschaft für Endokrinologie. Acta Endocrinol 1992; 124: 88
  • Fuhrmann U, Krattenmacher R, Slater E P, et al. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 1996; 54: 243–51
  • Oelkers W, Schöneshöfer M, Blümel A. Effects of progesterone and four synthetic progestagens on sodium balance and the renin–aldosterone system in man. J Clin Endocrinol Metab 1974; 39: 882–90
  • Sundsfjord J A, Aakvaag A. Plasma angiotensin II and aldosterone excretion during the menstrual cycle. Acta Endocrinol (Copenh) 1970; 64: 452–8
  • Von Rauscher H. Die Bedeutung des Zervixfaktors im Rahmen des Sterilitätsproblems. Wien Med Wochenschr 1966; 42/43: 903–9
  • Hoogland H J, Skouby S K. Ultrasound evaluation of ovarian activity under oral contraceptives. Contraception 1993; 47: 583–90
  • Oelkers W, Foidart J M, Dombrovicz N, et al. Effects of a new oral contraceptive containing an antimineralo-corticoid progestogen, drospirenone, on the renin–aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995; 80: 1816–21

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.